← Back to Search

Behavioral Intervention

Health Communication Intervention for HPV Vaccination Hesitancy

Research Sponsored by Meharry Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Study Summary

This trial will test whether a tailored, health communication intervention can increase HPV vaccination rates among underserved, vaccine hesitant parents.

Who is the study for?
This trial is for parents at Meharry Medical College who previously refused HPV vaccination for their kids aged 11-18, own a smartphone, speak English, and have an upcoming clinic appointment. Healthcare providers involved in primary care to this age group are also eligible. Those with vaccinated children or never offered the vaccine, non-English speakers, and without smartphones or scheduled visits cannot join.Check my eligibility
What is being tested?
The study tests a mobile phone-based web-page intervention designed to educate and encourage HPV vaccine-hesitant parents to vaccinate their adolescents against HPV. It aims to see if tailored health communication before doctor's visits can increase vaccination rates among these families.See study design
What are the potential side effects?
Since the intervention involves educational material rather than medical treatment, there are no direct side effects like those associated with drugs or vaccines. However, participants may experience changes in attitudes towards vaccinations.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Data collection processes
Recruitment Rates
Retention Rates
Secondary outcome measures
HPV vaccine rates

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Mobile Phone-Based Web-Page: HPV vaccineExperimental Treatment1 Intervention
Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit, tailored education information on the HPV vaccine via a text message with a website link.
Group II: Mobile Phone-Based Web-Page: Healthy LifestylesActive Control1 Intervention
Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit education information on an unrelated topic (e.g., healthy eating and physical activity) via a text message with a website link.

Find a Location

Who is running the clinical trial?

Meharry Medical CollegeLead Sponsor
18 Previous Clinical Trials
5,740 Total Patients Enrolled

Media Library

HPV vaccine (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04380623 — N/A
Human Papillomavirus Research Study Groups: Mobile Phone-Based Web-Page: HPV vaccine, Mobile Phone-Based Web-Page: Healthy Lifestyles
HPV vaccine (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04380623 — N/A
Human Papillomavirus Clinical Trial 2023: HPV vaccine Highlights & Side Effects. Trial Name: NCT04380623 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many patients are being included in the research?

"That is accurate. The clinical trial is listed as currently active on clinicaltrials.gov. The study was first posted on February 15th, 2021 and was last updated on September 6th, 2021. The trial is looking for 244 patients at a single site."

Answered by AI
~61 spots leftby Feb 2025